CytoHub, Inc., a pioneering developer of intelligent technologies for cell therapy and regenerative medicine, announced the strategic addition of three top industry experts to its team.
LA JOLLA, Calif.--(BUSINESS WIRE)-- CytoHub, Inc., a pioneering developer of intelligent technologies for cell therapy and regenerative medicine, today announced the strategic addition of three top industry experts to its team. David DiGiusto, Ph.D., joins as Technical, Scientific, and Strategic Advisor; Aitor Aguirre, Ph.D., as Scientific Advisor and Lead of Organoid Platform; and Frank Teoh as VP of Engineering, Global Head of BioEngineAI™ Platform.
These appointments mark a significant enhancement of CytoHub’s leadership, aligning with the company’s commitment to advancing biomanufacturing innovations in cell therapy and regenerative medicine. David DiGiusto, Ph.D., brings over three decades of experience in translational medicine and GMP compliant iPSC derived cells as therapeutics agents and biologics manufacturing. Aitor Aguirre, Ph.D., a distinguished researcher in tissue engineering and Associate Professor of Biomedical Engineering at MSU, will spearhead the company’s new Organoid Platform, and Frank Teoh, with extensive experience in Machine Learning, Artificial Intelligence and Cloud services, will lead the BioEngineAI™ Platform.
“The combined expertise of David, Aitor, and Frank is pivotal as we propel our innovations and make advanced cell therapies and regenerative medicine more accessible and affordable for everyone,” said Rajib Biswas, Ph.D., Founder and CEO of CytoHub, adding further, “Their addition positions CytoHub at the forefront of scientific and technical innovation.”
David DiGiusto, Ph.D., expressed his enthusiasm: “Joining CytoHub offers a thrilling opportunity to harness cutting-edge technologies vital for advancing biomanufacturing processes. These innovations are crucial for the field of regenerative medicine, and CytoHub will be at the center of this movement.”
Aitor Aguirre, Ph.D., added, “Novel organoid technologies are revolutionizing regenerative medicine, and I am eager to accelerate ethical drug development with state-of-the-art AI and human organoid technologies at CytoHub.”
Frank Teoh also reflected on his new role and stated, “Integrating AI and ML to scale biomanufacturing marks an exciting era. CytoHub is at the forefront of this industrialized biology, driving cell therapy and regenerative medicine innovations. It’s thrilling to join a pioneering force in the field.”
About CytoHub, Inc.:
CytoHub, Inc. is a biotech company dedicated to transforming cell therapy and regenerative medicine development and biomanufacturing with its innovative technologies and platforms. With a commitment to excellence and a focus on pioneering solutions, CytoHub aims to bridge the gap between laboratory research and practical medical applications, ultimately improving patient outcomes worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240505712967/en/
Source: CytoHub, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20240505712967/en
